Please ensure Javascript is enabled for purposes of website accessibility

Bristol-Myers Squibb and BioMotiv Launch Fibrosis Specialist Anteros Pharmaceuticals

By Brian Orelli, PhD - Feb 4, 2020 at 12:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big pharma has the right to acquire the start-up later a predetermined price.

Bristol-Myers Squibb (BMY 1.29%) and drug development accelerator BioMotiv have launched Anteros Pharmaceuticals, a biotech company focused on developing drugs for fibrotic and other inflammatory diseases. The new company is based on discoveries on an undisclosed target made at Yale University, which were licensed by Bristol-Myers and then assigned to Anteros. The initial work already includes a series of small-molecule drug candidates against the target.

BioMotiv and Bristol-Myers have been working together for five months through a partnership to establish multiple new companies. Anteros is the first start-up to emerge from the relationship.

BioMotiv will be responsible for research and development at Anteros. Once the company has a preclinical candidate, Bristol-Myers will have the option to purchase Anteros at a pre-specified price.

Scientist working in a lab

Image source: Getty Images.

Large drug companies have been doing this type of build-to-buy model for a while. Biogen, Celgene -- now part of Bristol-Myers -- and GlaxoSmithKline have all established partnerships with venture capital funds to create start-ups that the drugmakers have the option to eventually acquire. Johnson & Johnson and Bayer have taken a different approach, establishing their own no-strings-attached incubators to help start-ups grow while keeping a watchful eye on new technologies.

The model likely costs the companies more to develop individual drugs, but it reduces the risk of failure and keeps their research divisions at a manageable size. The model could also result in drugs being developed faster. A singularly focused small biotech may be more motivated to develop a candidate treatment more quickly than a larger pharmaceutical company with multiple interests.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$79.98 (1.29%) $1.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.